AVAX Technologies, Inc. (AVXT) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AVXT representa a AVAX Technologies, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). La acción obtiene una puntuación de 50/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026AVAX Technologies, Inc. (AVXT) Resumen de Asistencia Médica y Tuberías
AVAX Technologies, Inc. is a development-stage biopharmaceutical company specializing in autologous cell vaccine technologies for cancer treatment, including melanoma, ovarian cancer, and non-small cell lung cancer. With Phase II clinical trials completed for M-VAX and O-VAX, the company operates in a competitive biotechnology landscape.
Tesis de Inversión
AVAX Technologies, Inc. presents a high-risk, high-reward investment profile typical of development-stage biotechnology companies. The company's focus on autologous cell vaccine technologies for cancer treatment offers potential for significant returns if its product candidates successfully navigate clinical trials and regulatory approval. However, the company's negative profit margin of -1038.8% underscores its reliance on future funding or partnerships to sustain operations. Key value drivers include the successful advancement of M-VAX, O-VAX, and LungVax through clinical trials. Upcoming clinical trial results will be critical catalysts. The company's small size and limited resources, with only 9 employees, pose operational risks. Investors should closely monitor clinical trial progress, regulatory milestones, and the company's ability to secure additional funding.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- AVAX Technologies, Inc. operates in the high-growth biotechnology sector, focusing on innovative cancer treatment solutions.
- The company's product candidates, including M-VAX and O-VAX, have completed Phase II clinical trials, indicating some progress in development.
- AVAX Technologies, Inc. has a high gross margin of 100.0%, but this is offset by a significant negative profit margin of -1038.8%, highlighting its development stage and high R&D expenses.
- The company's market capitalization is $0.00B, reflecting its early stage and speculative nature.
- AVAX Technologies, Inc. has a beta of -55.48, indicating a high degree of volatility and potential for large price swings.
Competidores y Pares
Fortalezas
- Proprietary autologous cell vaccine technology.
- Product candidates in Phase II clinical trials.
- Focus on personalized cancer treatment.
- Experienced leadership in biotechnology.
Debilidades
- Development stage company with no approved products.
- Limited financial resources and small employee base.
- High reliance on successful clinical trial outcomes.
- Negative profit margin and dependence on external funding.
Catalizadores
- Upcoming: Clinical trial results for LungVax.
- Upcoming: Potential partnerships with pharmaceutical companies.
- Ongoing: Research and development of new cancer vaccine candidates.
- Ongoing: Efforts to secure grant funding and government support.
Riesgos
- Potential: Clinical trial failures or delays.
- Potential: Regulatory hurdles and approval delays.
- Ongoing: Competition from other cancer therapies.
- Ongoing: Inability to secure additional funding.
- Potential: Limited liquidity due to OTC market trading.
Oportunidades de crecimiento
- Advancement of LungVax for Non-Small Cell Lung Cancer: Lung cancer represents a significant market opportunity, with non-small cell lung cancer (NSCLC) being the most prevalent form. Successful clinical trials and subsequent regulatory approval for LungVax could drive substantial revenue growth for AVAX Technologies. The timeline for this growth opportunity depends on the pace of clinical development and regulatory review, potentially spanning several years. The addressable market is substantial, with the global lung cancer therapeutics market projected to reach billions of dollars.
- Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies could provide AVAX Technologies with access to additional funding, expertise, and resources to accelerate the development and commercialization of its product candidates. These collaborations can take the form of licensing agreements, joint ventures, or co-development partnerships. The timeline for securing such partnerships is uncertain but could occur within the next 1-3 years. Successful partnerships would validate the company's technology and enhance its market position.
- Expansion of Autologous Cell Vaccine Technology to Other Cancer Types: AVAX Technologies could leverage its autologous cell vaccine technology platform to develop new product candidates for other types of cancer beyond melanoma, ovarian cancer, and non-small cell lung cancer. This would diversify the company's pipeline and expand its addressable market. The timeline for this expansion depends on the availability of funding and the success of preclinical research. The market for cancer vaccines is growing, driven by advances in immunotherapy and personalized medicine.
- Out-Licensing of M-VAX and O-VAX: While AVAX Technologies continues to develop M-VAX and O-VAX, the company could explore out-licensing these product candidates to other companies for further development and commercialization. This would generate upfront revenue and potential milestone payments, providing AVAX Technologies with additional capital to invest in its other programs. The timeline for out-licensing depends on the attractiveness of the product candidates and the willingness of other companies to acquire the rights. The terms of any out-licensing agreement would vary depending on the specific circumstances.
- Securing Grant Funding and Government Support: AVAX Technologies could pursue grant funding from government agencies and non-profit organizations to support its research and development activities. These grants can provide non-dilutive funding, reducing the company's reliance on equity financing. The timeline for securing grant funding is uncertain and depends on the availability of funds and the competitiveness of the applications. Successful grant applications would validate the company's technology and provide valuable resources for its development programs.
Oportunidades
- Advancement of LungVax into later-stage clinical trials.
- Partnerships with larger pharmaceutical companies.
- Expansion of technology to other cancer types.
- Out-licensing of M-VAX and O-VAX.
Amenazas
- Clinical trial failures or delays.
- Regulatory hurdles and approval delays.
- Competition from other cancer therapies.
- Inability to secure additional funding.
Ventajas competitivas
- Proprietary autologous cell vaccine technology.
- Patents protecting their vaccine candidates and methods.
- Clinical data supporting the safety and efficacy of their products.
- Expertise in personalized cancer vaccine development.
Acerca de AVXT
AVAX Technologies, Inc., founded in 1990 and based in Philadelphia, Pennsylvania, is a biopharmaceutical company in the development stage. The company focuses on autologous cell vaccine technologies designed for cancer treatment. Its origins trace back to Walden Laboratories, Inc., before rebranding to AVAX Technologies, Inc. in March 1996. The company's pipeline features product candidates like M-VAX, intended for melanoma treatment, and O-VAX, targeting ovarian cancer, both of which have completed Phase II clinical trials. Additionally, AVAX Technologies is developing LungVax for the treatment of non-small cell lung cancer. These autologous cell vaccines are designed to utilize a patient's own cells to stimulate an immune response against cancer cells. As a development stage company, AVAX Technologies is currently focused on advancing its product candidates through the clinical trial process. The company operates within the biotechnology sector, which is characterized by high research and development costs, regulatory hurdles, and competition from other companies developing cancer therapies. With a small team of 9 employees, AVAX Technologies seeks to make an impact in the field of cancer immunotherapy.
Qué hacen
- Develop autologous cell vaccine technologies for cancer treatment.
- Focus on creating personalized cancer vaccines using a patient's own cells.
- Develop M-VAX for the treatment of melanoma.
- Develop O-VAX for the treatment of ovarian cancer.
- Develop LungVax for the treatment of non-small cell lung cancer.
- Conduct clinical trials to evaluate the safety and efficacy of their vaccine candidates.
- Seek regulatory approval for their products from agencies like the FDA.
Modelo de Negocio
- Develop and patent autologous cell vaccine technologies.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval for their vaccine products.
- Potentially partner with larger pharmaceutical companies for commercialization.
Contexto de la Industria
AVAX Technologies, Inc. operates within the biotechnology industry, a sector characterized by intense research and development, stringent regulatory requirements, and high levels of competition. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like AVAX Technologies, Inc. are focused on developing novel therapies, including immunotherapies and cell-based vaccines, to address unmet needs in cancer treatment. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share in this lucrative sector.
Clientes Clave
- Cancer patients seeking innovative treatment options.
- Oncologists and medical professionals who treat cancer patients.
- Hospitals and cancer centers that administer cancer therapies.
- Potential pharmaceutical partners for licensing or co-development agreements.
Finanzas
Gráfico e información
Precio de la acción de AVAX Technologies, Inc. (AVXT): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para AVXT.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para AVXT.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para AVXT.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de AVXT en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Adele Sommerfeld
CEO
Adele Sommerfeld serves as the CEO of AVAX Technologies, Inc., leading a team of 9 employees. Her background includes experience in the biotechnology industry, with a focus on pharmaceutical development and management. She has a proven track record in guiding early-stage companies through critical phases of growth and development. Her expertise encompasses strategic planning, fundraising, and clinical trial management. Sommerfeld's educational background includes advanced degrees in biology and business administration.
Historial: Under Adele Sommerfeld's leadership, AVAX Technologies, Inc. has advanced its product candidates, including M-VAX and O-VAX, through Phase II clinical trials. She has focused on securing funding and building strategic partnerships to support the company's research and development efforts. Her tenure has been marked by a commitment to advancing autologous cell vaccine technologies for cancer treatment.
Información del mercado OTC de AVXT
The OTC Other tier represents the lowest tier of the OTC market, indicating that AVAX Technologies, Inc. may not meet the minimum financial standards or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity may be thin. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may be subject to greater risks. The OTC Other tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Thin trading volume and potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Potential for delisting or suspension of trading.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's stock price and trading volume.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC Other stocks.
- Established history of operations since 1990.
- Focus on developing innovative cancer treatments.
- Completion of Phase II clinical trials for product candidates.
- Presence of a CEO and management team.
- Headquarters located in Philadelphia, Pennsylvania.
Lo Que los Inversores Preguntan Sobre AVAX Technologies, Inc. (AVXT)
¿Cuáles son los factores clave para evaluar AVXT?
AVAX Technologies, Inc. (AVXT) actualmente tiene una puntuación IA de 50/100, indicando puntuación moderada. Fortaleza clave: Proprietary autologous cell vaccine technology.. Riesgo principal a monitorear: Potential: Clinical trial failures or delays.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de AVXT?
AVXT actualmente puntúa 50/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de AVXT?
Los precios de AVXT se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre AVXT?
La cobertura de analistas para AVXT incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en AVXT?
Las categorías de riesgo para AVXT incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures or delays.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de AVXT?
La relación P/E para AVXT compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está AVXT sobrevalorada o infravalorada?
Determinar si AVAX Technologies, Inc. (AVXT) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de AVXT?
AVAX Technologies, Inc. (AVXT) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available sources and may be limited due to the company's OTC status and development stage.